Granules inks pact with Par Pharmaceutical

G Naga Sridhar Hyderabad | Updated on January 19, 2018 Published on January 21, 2016

Granules USA, the wholly owned subsidiary of Granules India Ltd, has entered into an agreement with Par Pharmaceutical Inc., a subsidiary of Endo International Plc, to market the generic version of over the counter (drug) omeprazole and sodium bicarbonate in North America.

This is line with an approval from the US Food and Drug Administration (USFDA) which is currently expected in July 2016.

Par Pharmaceutical’s omeprazole and sodium bicarbonate is the generic equivalent of Merck/MSD Consumer Care Inc’s Zegerid.

Omeprazole is a proton pump inhibitor (PPI) that decreases the production of stomach acid. Sodium bicarbonate is an antacid that raises stomach pH to keep the omeprazole from breaking down in stomach acid.

"Through this exclusive agreement with Par Pharmaceutical, we can strengthen our OTC product basket and widen our offerings in the North American store brand market for meeting retailers’ and consumers’ desire for competitive market choices and alternatives,’’ Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India Ltd, said in a release issued here on Thursday.

Published on January 21, 2016
This article is closed for comments.
Please Email the Editor